GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AptaBio Therapeutics 293780.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

4,730

-3.47%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩3.70bn

FY2017FY2025

Net income

−₩16.35bn

FY2017FY2025

Free cash flow

−₩15.33bn

FY2017FY2025

Shareholders' equity

₩47.18bn

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue₩3.70bn₩3.36bn₩323.9m₩48.4m₩223.7m₩341.0m₩1.02bn₩1.45bn₩300.1m
Research and development₩10.50bn₩14.59bn₩12.38bn₩6.20bn₩9.08bn₩3.83bn———
Operating income−₩15.54bn−₩26.41bn−₩16.37bn−₩9.51bn−₩11.37bn−₩6.06bn−₩7.15bn−₩3.36bn−₩2.14bn
Net income−₩16.35bn−₩29.38bn−₩12.06bn−₩10.56bn−₩10.69bn−₩3.92bn−₩6.30bn−₩4.06bn−₩31.12bn
Diluted earnings per share-581.85-1,092.87-540.91-473.78-481.57-176.60-289.38-234.36-3,442.77

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets₩60.03bn₩77.43bn₩92.52bn₩56.11bn₩64.91bn₩75.44bn₩77.40bn₩20.33bn₩11.00bn
Cash and short-term investments————₩22.91bn₩42.82bn₩46.16bn₩19.69bn₩10.57bn
Total liabilities₩12.84bn₩23.24bn₩31.16bn₩3.74bn₩3.25bn₩3.40bn₩2.25bn₩2.02bn₩42.54bn
Debt——₩13.57bn—₩101.3m₩61.0m₩86.0m—₩7.02bn
Shareholders' equity₩47.18bn₩54.20bn₩61.36bn₩52.37bn₩61.67bn₩72.04bn₩75.16bn₩18.31bn−₩31.54bn
Shares outstanding28m27m22m22m22m22m22m17m9m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−₩15.28bn−₩12.16bn−₩14.10bn−₩6.83bn−₩8.90bn−₩3.79bn−₩6.00bn−₩1.75bn−₩1.79bn
Capital spending−₩58.7m−₩240.2m−₩167.4m−₩1.04bn−₩161.7m−₩1.69bn−₩2.78bn−₩27.7m−₩8.9m
Free cash flow−₩15.33bn−₩12.40bn−₩14.26bn−₩7.87bn−₩9.06bn−₩5.48bn−₩8.79bn−₩1.78bn−₩1.80bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩1.60bn₩957.4m₩1.00bn₩1.19bn₩1.12bn₩382.7m₩744.0m₩859.4m
Operating income−₩3.57bn−₩6.31bn−₩5.72bn−₩3.38bn−₩3.60bn−₩2.63bn−₩8.68bn—
Net income₩1.12bn−₩6.44bn−₩6.47bn−₩3.07bn−₩4.23bn−₩2.58bn−₩10.35bn−₩8.03bn
Diluted earnings per share39.71-229.41-230.37-114.13-157.24-95.96-385.11-324.56
Cash from operations−₩2.63bn−₩7.99bn−₩4.02bn−₩2.73bn−₩1.98bn−₩6.55bn−₩12.16bn−₩8.04bn
Capital spending—−₩10.0m−₩4.0m−₩16.0m−₩1.0m−₩36.0m−₩240.0m−₩3.0m
Free cash flow—−₩8.00bn−₩4.02bn−₩2.74bn−₩1.98bn−₩6.58bn−₩12.40bn−₩8.04bn
Total assets₩54.40bn₩53.75bn₩60.03bn₩67.12bn₩69.71bn₩71.93bn₩77.43bn₩83.32bn
Cash and short-term investments—————₩24.91bn₩31.50bn₩37.96bn
Debt—————₩115.9m₩122.0m₩13.56bn
Shareholders' equity₩42.20bn₩40.89bn₩47.18bn₩44.61bn₩47.50bn₩51.73bn₩54.20bn₩48.97bn

Financial ratios

Data as of 5 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating margin-420.1%-785.9%-5055.6%-19661.2%-5081.9%-1778.3%———
Net margin-442.0%-874.1%-3724.2%-21849.3%-4778.8%-1149.1%———
Return on equity-34.6%-54.2%-19.7%-20.2%-17.3%-5.4%———
Return on assets-27.2%-37.9%-13.0%-18.8%-16.5%-5.2%———
Revenue growth10.0%937.8%569.8%-78.4%-34.4%-66.5%———
Earnings growth-44.4%143.6%14.2%-1.2%172.8%-37.8%———
Current ratio2.61x1.79x70.27x19.63x30.19x54.60x———
Debt to equity——0.22x—0.00x0.00x0.00x0.00x-0.15x
Equity ratio78.6%70.0%66.3%93.3%95.0%95.5%———
Interest coverage-7.34x-473.31x-419.76x-392.39x-469.17x-327.30x———
R&D as a share of sales284.0%434.1%3822.7%12816.5%4058.6%1122.7%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue324.5%61.1%—
Operating income17.8%20.7%—
Net income15.7%33.1%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-16.1-5.8-16.7-22.5-77.3-143.8-59.8
Price to sales71.051.0————369.6

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-for-1 split · 24 Aug 2021

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.